Gene Therapy Market - Global Gene Therapy Market Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

Description

The global gene therapy market is on the brink of a revolutionary transformation, with a projected Compound Annual Growth Rate (CAGR) of 19.6% between 2023 and 2030, according to the latest market research report by Fairfield Market Research. The market is set to surge from a value of $7.8 billion in 2022 to a staggering $27.3 billion by 2030, driven by groundbreaking advancements in genetic research and technology.

Advancements in Genetic Research Drive Market Growth

A key catalyst propelling this remarkable growth is the continuous evolution of genetic research and technology, including the game-changing CRISPR-Cas9 and other gene editing tools. These innovations have significantly deepened our understanding of genes and their pivotal role in various diseases, paving the way for innovative therapies.

Surging Incidence of Genetic Disorders Fuels Market Expansion

Another major driver of market growth is the rising incidence of genetic disorders, both congenital and acquired. This surge in genetic ailments has spurred the development and adoption of gene therapy as a promising and viable treatment option, offering hope to patients and healthcare providers alike.

Viral Vectors Dominate the Market

In 2022, the viral vectors category dominated the gene therapy industry. Viral vectors, including adeno-associated virus (AAV) vectors, lentiviral vectors, and retroviral vectors, have historically been the go-to tools in gene therapy due to their efficiency in delivering genetic material into target cells. Among these, adeno-associated virus (AAV) vectors have gained prominence for their safety profile and effectiveness in gene delivery.

Cancer Segment Takes the Lead

In terms of market share, the cancer segment is expected to lead the gene therapy market. The high prevalence of cancer cases worldwide and the potential of gene therapy to offer innovative and effective treatments have driven significant attention toward gene therapies for various types of cancers. Advancements in gene-based cancer therapies, including CAR-T cell therapy and oncolytic viral therapies, have shown promising results in clinical trials and have even been approved for certain cancer types.

In Vivo Gene Therapy Gains Prominence

In 2022, the in vivo category was at the forefront of the market. In vivo gene therapy offers targeted and precise treatments directly within the patient's physiological environment. This approach is easier to administer and has the potential for efficient therapeutic action. In vivo gene therapies find applications across a wide range of diseases, including genetic disorders, various types of cancers, cardiovascular diseases, and neurological disorders.

Neurological Diseases on the Rise

Neurological diseases represent a significant category in the gene therapy market. These disorders encompass a broad spectrum of conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. Conditions such as Parkinson's disease, Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and various forms of ataxia fall within this category.

North America Leads in Innovation and Investment

North America is poised to account for the largest share of the global gene therapy market, driven by its robust technological infrastructure and economic conditions. Renowned research institutions, academic centers, and biotech companies in North America are at the forefront of groundbreaking research and innovation in gene therapy. The region frequently serves as the epicenter for pioneering gene therapies, attracting substantial investments and fostering collaboration.

Asia Pacific Rises on the Global Stage

The gene therapy market is rapidly expanding in the Asia Pacific region, driven by rapid economic growth and technological advancements. Increased healthcare expenditure and research funding, fueled by rising disposable incomes, provide ample resources for research, development, and the adoption of cutting-edge technologies like gene therapy.

Challenges and Regulatory Impact

Despite its remarkable growth prospects, the gene therapy market faces challenges, including prohibitive costs associated with research, development, and manufacturing, as well as the lack of long-term data and follow-up studies to ensure safety and efficacy.

Regulatory Environment Shapes the Industry

Over the past three years, the regulatory environment has played a pivotal role in shaping the gene therapy market. Regulatory bodies, such as the US FDA and the European Medicines Agency (EMA), oversee the safety, efficacy, and quality of gene therapies, and their guidelines and approval processes significantly influence research, development, and market access. Expedited pathways and flexible frameworks have been introduced to accelerate approvals, particularly for treatments addressing rare, life-threatening diseases.

Leaders in the Global Gene Therapy Space

The global gene therapy market is characterized by a consolidated landscape, with a few major players dominating the industry. Leading companies include:

1. Merck KGaA
2. Novartis AG
3. AstraZeneca Plc.
4. BIOCAD
5. Crinetics Pharmaceuticals Inc.
6. EffRx Pharmaceuticals S.A.
7. Euroscreen S.A.
8. Vicore Pharma AB
9. Amgen
10. Bristol-Myers Squibb
11. Cell Genesys Inc.
12. Adaptimmune Therapeutics plc.
13. Achieve Life Science Inc.
14. BioCanCell Ltd.
15. Genelux Corporation
16. Advantagene Inc.
17. GenVec Inc
18. GlaxoSmithKline PLC

Global Gene Therapy Market is Segmented as Below:

By Vector:

Grade Non-viral Vectors
- Oligonucleotides
- Other Non-viral Vectors

Viral Vectors
- Retro Viral Vectors
- Adeno-associated Virus Vectors
- Others Viral Vectors

By Indication:

Neurological Diseases
Cancer
DMD (Duchenne Muscular Dystrophy)
Hepatological Diseases
Other Indications

By Delivery Method:

In Vivo
Ex Vivo

By Sales Channel:

Offline Sales Channel
- Supermarkets/Hypermarkets
- Departmental Stores
- Convenience Store
- Other Sales Channel

Online Sales Channel
- Company Website
- E-commerce Platform

By Geographic Coverage:

North America
U.S.
Canada

Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe

Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America

Middle East & Africa
- GCC
- South Africa
- Egypt
- Nigeria
- Rest of the Middle East & Africa

1. Executive Summary

1.1. Global Gene Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Gene Therapy Market Outlook, 2018 - 2030

3.1. Global Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. Non-viral Vectors
    - 3.1.1.1.1. Oligonucleotides
    - 3.1.1.1.2. Other Non-viral Vectors
  - 3.1.1.2. Viral Vectors
    - 3.1.1.2.1. Retro Viral Vectors
    - 3.1.1.2.2. Adeno-associated Virus Vectors
    - 3.1.1.2.3. Others Viral Vectors
3.2. Global Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 3.2.1. Key Highlights
  - 3.2.1.1. Neurological Diseases
  - 3.2.1.2. Cancer
  - 3.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 3.2.1.4. Hepatological Diseases
  - 3.2.1.5. Other Indications
3.3. Global Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 3.3.1. Key Highlights
  - 3.3.1.1. In Vivo
  - 3.3.1.2. Ex Vivo
3.4. Global Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 3.4.1. Key Highlights
  - 3.4.1.1. Offline Sales Channel
    - 3.4.1.1.1. Supermarkets/Hypermarkets
    - 3.4.1.1.2. Departmental Stores
    - 3.4.1.1.3. Convenience Store
    - 3.4.1.1.4. Other
  - 3.4.1.2. Online Sales Channel
    - 3.4.1.2.1. Company Website
    - 3.4.1.2.2. E-commerce Platform
3.5. Global Gene Therapy Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Gene Therapy Market Outlook, 2018 - 2030

4.1. North America Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Non-viral Vectors
    - 4.1.1.1.1. Oligonucleotides
    - 4.1.1.1.2. Other Non-viral Vectors
  - 4.1.1.2. Viral Vectors
    - 4.1.1.2.1. Retro Viral Vectors
    - 4.1.1.2.2. Adeno-associated Virus Vectors
    - 4.1.1.2.3. Others Viral Vectors
4.2. North America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Neurological Diseases
  - 4.2.1.2. Cancer
  - 4.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 4.2.1.4. Hepatological Diseases
  - 4.2.1.5. Other Indications
4.3. North America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. In Vivo
  - 4.3.1.2. Ex Vivo
4.4. North America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 4.4.1. Key Highlights
  - 4.4.1.1. Offline Sales Channel
    - 4.4.1.1.1. Supermarkets/Hypermarkets
    - 4.4.1.1.2. Departmental Stores
    - 4.4.1.1.3. Convenience Store
    - 4.4.1.1.4. Other Sales Channel
  - 4.4.1.2. Online Sales Channel
    - 4.4.1.2.1. Company Website
    - 4.4.1.2.2. E-commerce Platform
4.5. North America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 4.5.1.2. U.S. Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 4.5.1.3. U.S. Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 4.5.1.4. U.S. Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 4.5.1.5. Canada Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 4.5.1.6. Canada Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 4.5.1.7. Canada Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 4.5.1.8. Canada Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Gene Therapy Market Outlook, 2018 - 2030

5.1. Europe Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. Non-viral Vectors
    - 5.1.1.1.1. Oligonucleotides
    - 5.1.1.1.2. Other Non-viral Vectors
  - 5.1.1.2. Viral Vectors
    - 5.1.1.2.1. Retro Viral Vectors
    - 5.1.1.2.2. Adeno-associated Virus Vectors
    - 5.1.1.2.3. Others Viral Vectors
5.2. Europe Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Neurological Diseases
  - 5.2.1.2. Cancer
  - 5.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 5.2.1.4. Hepatological Diseases
  - 5.2.1.5. Other Indications
5.3. Europe Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. In Vivo
  - 5.3.1.2. Ex Vivo
5.4. Europe Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 5.4.1. Key Highlights
  - 5.4.1.1. Offline Sales Channel
    - 5.4.1.1.1. Supermarkets/Hypermarkets
    - 5.4.1.1.2. Departmental Stores
    - 5.4.1.1.3. Convenience Store
    - 5.4.1.1.4. Other Sales Channel
  - 5.4.1.2. Online Sales Channel
    - 5.4.1.2.1. Company Website
    - 5.4.1.2.2. E-commerce Platform
5.5. Europe Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.2. Germany Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.3. Germany Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.4. Germany Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.5. U.K. Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.6. U.K. Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.7. U.K. Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.8. U.K. Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.9. France Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.10. France Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.11. France Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.12. France Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.13. Italy Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.14. Italy Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.15. Italy Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.16. Italy Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.17. Turkey Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.18. Turkey Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.19. Turkey Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.20. Turkey Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.21. Russia Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.22. Russia Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.23. Russia Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.24. Russia Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 5.5.1.25. Rest of Europe Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 5.5.1.26. Rest of Europe Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.27. Rest of Europe Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 5.5.1.28. Rest of Europe Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Gene Therapy Market Outlook, 2018 - 2030

6.1. Asia Pacific Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 6.1.1. Key Highlights
  - 6.1.1.1. Non-viral Vectors
    - 6.1.1.1.1. Oligonucleotides
    - 6.1.1.1.2. Other Non-viral Vectors
  - 6.1.1.2. Viral Vectors
    - 6.1.1.2.1. Retro Viral Vectors
    - 6.1.1.2.2. Adeno-associated Virus Vectors
    - 6.1.1.2.3. Others Viral Vectors
6.2. Asia Pacific Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Neurological Diseases
  - 6.2.1.2. Cancer
  - 6.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 6.2.1.4. Hepatological Diseases
  - 6.2.1.5. Other Indications
6.3. Asia Pacific Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. In Vivo
  - 6.3.1.2. Ex Vivo
6.4. Asia Pacific Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 6.4.1. Key Highlights
  - 6.4.1.1. Offline Sales Channel
    - 6.4.1.1.1. Supermarkets/Hypermarkets
    - 6.4.1.1.2. Departmental Stores
    - 6.4.1.1.3. Convenience Store
    - 6.4.1.1.4. Other Sales Channel
  - 6.4.1.2. Online Sales Channel
    - 6.4.1.2.1. Company Website
    - 6.4.1.2.2. E-commerce Platform
6.5. Asia Pacific Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 6.5.1. Key Highlights
  - 6.5.1.1. China Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.2. China Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.3. China Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.4. China Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 6.5.1.5. Japan Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.6. Japan Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.7. Japan Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.8. Japan Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 6.5.1.9. South Korea Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.10. South Korea Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.11. South Korea Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.12. South Korea Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 6.5.1.13. India Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.14. India Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.15. India Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.16. India Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 6.5.1.17. Southeast Asia Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.18. Southeast Asia Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.19. Southeast Asia Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.20. Southeast Asia Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 6.5.1.21. Rest of Asia Pacific Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 6.5.1.22. Rest of Asia Pacific Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.23. Rest of Asia Pacific Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 6.5.1.24. Rest of Asia Pacific Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Gene Therapy Market Outlook, 2018 - 2030

7.1. Latin America Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. Non-viral Vectors
    - 7.1.1.1.1. Oligonucleotides
    - 7.1.1.1.2. Other Non-viral Vectors
  - 7.1.1.2. Viral Vectors
    - 7.1.1.2.1. Retro Viral Vectors
    - 7.1.1.2.2. Adeno-associated Virus Vectors
    - 7.1.1.2.3. Others Viral Vectors
7.2. Latin America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 7.2.1. Key Highlights
  - 7.2.1.1. Neurological Diseases
  - 7.2.1.2. Cancer
  - 7.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 7.2.1.4. Hepatological Diseases
  - 7.2.1.5. Other Indications
7.3. Latin America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 7.3.1. Key Highlights
  - 7.3.1.1. In Vivo
  - 7.3.1.2. Ex Vivo
7.4. Latin America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 7.4.1. Key Highlights
  - 7.4.1.1. Offline Sales Channel
    - 7.4.1.1.1. Supermarkets/Hypermarkets
    - 7.4.1.1.2. Departmental Stores
    - 7.4.1.1.3. Convenience Store
    - 7.4.1.1.4. Other Sales Channel
  - 7.4.1.2. Online Sales Channel
    - 7.4.1.2.1. Company Website
    - 7.4.1.2.2. E-commerce Platform
7.5. Latin America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 7.5.1.2. Brazil Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.3. Brazil Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 7.5.1.4. Brazil Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 7.5.1.5. Mexico Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 7.5.1.6. Mexico Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.7. Mexico Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 7.5.1.8. Mexico Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 7.5.1.9. Argentina Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 7.5.1.10. Argentina Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.11. Argentina Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 7.5.1.12. Argentina Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 7.5.1.13. Rest of Latin America Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 7.5.1.14. Rest of Latin America Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.15. Rest of Latin America Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 7.5.1.16. Rest of Latin America Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Gene Therapy Market Outlook, 2018 - 2030

8.1. Middle East & Africa Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. Non-viral Vectors
    - 8.1.1.1.1. Oligonucleotides
    - 8.1.1.1.2. Other Non-viral Vectors
  - 8.1.1.2. Viral Vectors
    - 8.1.1.2.1. Retro Viral Vectors
    - 8.1.1.2.2. Adeno-associated Virus Vectors
    - 8.1.1.2.3. Others Viral Vectors
8.2. Middle East & Africa Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Neurological Diseases
  - 8.2.1.2. Cancer
  - 8.2.1.3. DMD (Duchenne Muscular Dystrophy)
  - 8.2.1.4. Hepatological Diseases
  - 8.2.1.5. Other Indications
8.3. Middle East & Africa Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. In Vivo
  - 8.3.1.2. Ex Vivo
8.4. Middle East & Africa Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
- 8.4.1. Key Highlights
  - 8.4.1.1. Offline Sales Channel
    - 8.4.1.1.1. Supermarkets/Hypermarkets
    - 8.4.1.1.2. Departmental Stores
    - 8.4.1.1.3. Convenience Store
    - 8.4.1.1.4. Other Sales Channel
  - 8.4.1.2. Online Sales Channel
    - 8.4.1.2.1. Company Website
    - 8.4.1.2.2. E-commerce Platform
8.5. Middle East & Africa Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 8.5.1.2. GCC Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.3. GCC Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 8.5.1.4. GCC Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 8.5.1.5. South Africa Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 8.5.1.6. South Africa Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.7. South Africa Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 8.5.1.8. South Africa Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 8.5.1.9. Egypt Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 8.5.1.10. Egypt Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.11. Egypt Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 8.5.1.12. Egypt Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 8.5.1.13. Nigeria Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 8.5.1.14. Nigeria Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.15. Nigeria Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 8.5.1.16. Nigeria Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
  - 8.5.1.17. Rest of Middle East & Africa Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
  - 8.5.1.18. Rest of Middle East & Africa Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.19. Rest of Middle East & Africa Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
  - 8.5.1.20. Rest of Middle East & Africa Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs Vector Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Merck KGaA
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Novartis AG
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. AstraZeneca Plc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. BIOCAD
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Crinetics Pharmaceuticals Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. EffRx Pharmaceuticals S.A.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Euroscreen S.A.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Vicore Pharma AB
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Bristol-Myers Squibb
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Cell Genesys Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Adaptimmune Therapeutics plc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Achieve Life Science Inc.
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. BioCanCell Ltd.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. Genelux Corporation
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Product Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. Advantagene Inc.
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Product Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development
- 9.4.16. GenVec Inc
  - 9.4.16.1. Company Overview
  - 9.4.16.2. Product Portfolio
  - 9.4.16.3. Financial Overview
  - 9.4.16.4. Business Strategies and Development
- 9.4.17. GlaxoSmithKline PLC
  - 9.4.17.1. Company Overview
  - 9.4.17.2. Product Portfolio
  - 9.4.17.3. Financial Overview
  - 9.4.17.4. Business Strategies and Development
- 9.4.18. Amgen Inc.
  - 9.4.18.1. Company Overview
  - 9.4.18.2. Product Portfolio
  - 9.4.18.3. Financial Overview
  - 9.4.18.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations